Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
accepted:
20
07
2023
medline:
25
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
The life expectancy of people living with HIV (PLWHIV) has significantly improved in recent decades, mostly due to antiretroviral (ARV) therapy. Aging can affect the pharmacokinetics of drugs and, as a consequence, increase the risk of drug interactions and toxicity that may impact treatment. The aim of this study was to carry out a systematic review of the literature on the effect of aging on ARV pharmacokinetics. Searches were performed in the BVS, EMBASE and PUBMED databases until November 2022. All studies available in English, Spanish and Portuguese investigating the pharmacokinetics of ARV approved by the US Food and Drug Administration (FDA) from 2005 to 2020 were selected. Peer-reviewed publications were included if they met all criteria: adults (≥ 18 years of age) living with or without HIV; report any pharmacokinetic parameter or plasma concentration of at least one of the following ARVs: tenofovir alafenamide fumarate (TAF); doravirine (DOR), rilpivirine (RIL) and etravirine (ETR); darunavir (DRV), tipranavir (TPV) and fostemsavir (FTR); dolutegravir (DTG), raltegravir (RAL), bictegravir (BIC) and elvitegravir (EVG); maraviroc (MVC); ibalizumab (IBA); cobicistat (COBI). Pharmacokinetic parameters were reported stratified per age group: young adults (aged 18-49 years) or older (age ≥ 50 years) and all studies were evaluated for quality. The review protocol was registered in the PROSPERO database (registration number CRD42021236432). Among 97 studies included, 20 reported pharmacokinetic evaluation in older individuals (age ≥ 50 years). Twenty five percent of the articles were phase I randomized clinical trials with HIV-negative participants and non-compartmental pharmacokinetic analysis presenting the parameters area under the curve (AUC) and peak drug concentration (C Exposure to DRV increases modestly with age, while exposure to BIC, DOR and RAL appears to be unaffected by age. As the available evidence to confirm a potential effect of aging on ARV pharmacokinetics is limited, further studies are necessary.
Sections du résumé
BACKGROUND AND OBJECTIVE
The life expectancy of people living with HIV (PLWHIV) has significantly improved in recent decades, mostly due to antiretroviral (ARV) therapy. Aging can affect the pharmacokinetics of drugs and, as a consequence, increase the risk of drug interactions and toxicity that may impact treatment. The aim of this study was to carry out a systematic review of the literature on the effect of aging on ARV pharmacokinetics.
METHODS
Searches were performed in the BVS, EMBASE and PUBMED databases until November 2022. All studies available in English, Spanish and Portuguese investigating the pharmacokinetics of ARV approved by the US Food and Drug Administration (FDA) from 2005 to 2020 were selected. Peer-reviewed publications were included if they met all criteria: adults (≥ 18 years of age) living with or without HIV; report any pharmacokinetic parameter or plasma concentration of at least one of the following ARVs: tenofovir alafenamide fumarate (TAF); doravirine (DOR), rilpivirine (RIL) and etravirine (ETR); darunavir (DRV), tipranavir (TPV) and fostemsavir (FTR); dolutegravir (DTG), raltegravir (RAL), bictegravir (BIC) and elvitegravir (EVG); maraviroc (MVC); ibalizumab (IBA); cobicistat (COBI). Pharmacokinetic parameters were reported stratified per age group: young adults (aged 18-49 years) or older (age ≥ 50 years) and all studies were evaluated for quality. The review protocol was registered in the PROSPERO database (registration number CRD42021236432).
RESULTS
Among 97 studies included, 20 reported pharmacokinetic evaluation in older individuals (age ≥ 50 years). Twenty five percent of the articles were phase I randomized clinical trials with HIV-negative participants and non-compartmental pharmacokinetic analysis presenting the parameters area under the curve (AUC) and peak drug concentration (C
CONCLUSION
Exposure to DRV increases modestly with age, while exposure to BIC, DOR and RAL appears to be unaffected by age. As the available evidence to confirm a potential effect of aging on ARV pharmacokinetics is limited, further studies are necessary.
Identifiants
pubmed: 37561283
doi: 10.1007/s40262-023-01291-x
pii: 10.1007/s40262-023-01291-x
doi:
Substances chimiques
Anti-HIV Agents
0
Tenofovir
99YXE507IL
Pharmaceutical Preparations
0
Anti-Retroviral Agents
0
Raltegravir Potassium
43Y000U234
Adenine
JAC85A2161
Darunavir
YO603Y8113
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1219-1230Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Aguiar RB, Leal MCC, Marques AP de O, Torres KMS, Tavares MTDB. Idosos vivendo com HIV—comportamento e conhecimento sobre sexualidade: revisão integrativa. Ciênc Saúde Coletiva. 2020;25:575–84.
HIVinfo. FDA Approval of HIV Medicines - A timeline with all the FDA approval dates for HIV medicines, categorized by drug class. 2022. https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines . Accessed 12 Jan 2022.
World Health Organization. HIV: from a devastating epidemic to a manageable chronic disease. WHO; 2017. https://www.who.int/publications/10-year-review/chapter-hiv.pdf . Accessed 12 Jan 2022.
CANOC Collaboration, Patterson S, Cescon A, Samji H, Chan K, Zhang W, et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015;15:274.
Hogg R. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–9.
doi: 10.1016/S0140-6736(08)61113-7
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8: e81355.
pubmed: 24367482
pmcid: 3867319
doi: 10.1371/journal.pone.0081355
Smiley CL, Rebeiro PF, Cesar C, Belaunzaran-Zamudio PF, Crabtree-Ramirez B, Padgett D, et al. Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study. Lancet HIV. 2021;8:e266–73.
pubmed: 33891877
pmcid: 8171816
doi: 10.1016/S2352-3018(20)30358-1
UNAIDS. 2020 Global AIDS update—seizing the moment tackling entrenched inequalities to end epidemics. UNAIDS; 2020. https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf . Accessed 12 Jan 2022.
Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, et al. Role of normalized T-cell subsets in predicting comorbidities in a large cohort of geriatric HIV-infected patients. J Acquir Immune Defic Syndr. 2017;76:338–42.
pubmed: 28708810
doi: 10.1097/QAI.0000000000001496
DeVaughn S, Müller-Oehring EM, Markey B, Brontë-Stewart HM, Schulte T. Aging with HIV-1 infection: motor functions, cognition, and attention—a comparison with Parkinson’s disease. Neuropsychol Rev. 2015;25:424–38.
pubmed: 26577508
pmcid: 5519342
doi: 10.1007/s11065-015-9305-x
Belaunzaran-Zamudio PF, Caro-Vega Y, Giganti MJ, Castilho JL, Crabtree-Ramirez BE, Shepherd BE, et al. Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America. Nunes BP, editor. PLoS One. 2020;15:e0233965.
Cardoso SW, Torres TS, Santini-Oliveira M, Marins LMS, Veloso VG, Grinsztejn B. Aging with HIV: a practical review. Braz J Infect Dis. 2013;17:464–79.
pubmed: 23711587
pmcid: 9428066
doi: 10.1016/j.bjid.2012.11.007
Chary A, Nguyen NN, Maiton K, Holodniy M. A review of drug–drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017;10(12):1329–52.
pubmed: 28922979
doi: 10.1080/17512433.2017.1377610
Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol. 2013;9:573–88.
pubmed: 23514375
pmcid: 3673886
doi: 10.1517/17425255.2013.781153
Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Intern AIDS Soc. 2020;23(2):e25449. https://onlinelibrary.wiley.com/doi/10.1002/jia2.25449 . Accessed 31 Jan 2022.
Chary A, Nguyen NN, Maiton K, Holodniy M. A review of drug–drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017;10:1329–52.
pubmed: 28922979
doi: 10.1080/17512433.2017.1377610
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.
pubmed: 21998278
doi: 10.1093/cid/cir627
Calcagno A, Moltó J, Borghetti A, Gervasoni C, Milesi M, Valle M, et al. Older age is associated with higher dolutegravir exposure in plasma and cerebrospinal fluid of people living with HIV. Clin Pharmacokinet. 2020;60:103–9.
doi: 10.1007/s40262-020-00916-9
Tyrberg E, Edén A, Eriksen J, Nilsson S, Treutiger CJ, Thalme A, et al. Higher plasma drug levels in elderly people living with HIV treated with darunavir. PLoS ONE. 2021;16: e0246171.
pubmed: 33539440
pmcid: 7861408
doi: 10.1371/journal.pone.0246171
PRISMA-P Group, Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
Fontela C, Castilla J, Juanbeltz R, Martínez-Baz I, Rivero M, O’Leary A, et al. Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016. Postgrad Med. 2018;130:317–24.
pubmed: 29486621
doi: 10.1080/00325481.2018.1446653
Maciel RA, Klück HM, Durand M, Sprinz E. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: a cross-sectional study. Int J Infect Dis. 2018;70:30–5.
pubmed: 29476902
doi: 10.1016/j.ijid.2018.02.009
Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, et al. A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs. Clin Pharmacokinet. 2019;58:747–66.
pubmed: 30406475
doi: 10.1007/s40262-018-0716-8
Calza L, Danese I, Colangeli V, Manfredi R, Magistrelli E, Verucchi G, et al. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. Infect Dis (Lond). 2015;47:625–36.
pubmed: 25875396
doi: 10.3109/23744235.2015.1034169
Vera JH, Jackson A, Dickinson L, Else L, Barber T, Mora-Peris B, et al. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV Clin Trials. 2015;16:39–42.
pubmed: 25777188
doi: 10.1179/1528433614Z.0000000006
Johnson DH, Sutherland D, Acosta EP, Erdem H, Richardson D, Haas DW. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: A single arm pharmacokinetic study. PLoS ONE. 2013;8(12): e82672.
pubmed: 24349334
pmcid: 3859605
doi: 10.1371/journal.pone.0082672
Cattaneo D, Puoti M, Sollima S, Moioli C, Foppa CU, Baldelli S, et al. Reduced raltegravir clearance in HIV-infected liver transplant recipients: An unexpected interaction with immunosuppressive therapy? J Antimicrob Chemother. 2016;71:1341–5.
pubmed: 26755497
doi: 10.1093/jac/dkv466
Calcagno A, Baietto L, Pagani N, Simiele M, Audagnotto S, D’Avolio A, et al. Voriconazole and atazanavir: A CYP2C19-dependent manageable drug-drug interaction. Pharmacogenomics. 2014;15:1281–6.
pubmed: 25155930
doi: 10.2217/pgs.14.92
Cattaneo D, Gervasoni C, Cozzi V, Baldelli S, Fucile S, Meraviglia P, et al. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. Pharmacol Res. 2012;65:198–203.
pubmed: 21958880
doi: 10.1016/j.phrs.2011.09.006
Cottrell ML, Patterson KB, Prince HMA, Jones A, White N, Wang R, et al. Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract. Antiviral Ther. 2015;20:795–803.
doi: 10.3851/IMP2968
Mogalian E, Stamm LM, Osinusi A, Brainard DM, Shen G, Ling KHJ, et al. Drug-Drug Interaction Studies between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Clin Infect Dis. 2018;67:934–40.
pubmed: 29522076
doi: 10.1093/cid/ciy201
Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS. 2013;27:1413–9.
pubmed: 23945503
doi: 10.1097/QAD.0b013e32835f2b49
Spinner CD, Wille F, Schwerdtfeger C, Thies P, Tanase U, Figura G, et al. Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data. AIDS Res Ther. 2015;12(1):1.
Taburet A-M, Sauvageon H, Grinsztejn B, Assuied A, Veloso V, Pilotto JH, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy. Clin Infect Dis. 2015;61:1328–35.
pubmed: 26105170
doi: 10.1093/cid/civ477
Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69:1079–85.
pubmed: 24343893
doi: 10.1093/jac/dkt483
Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52:3253–8.
pubmed: 18625763
pmcid: 2533504
doi: 10.1128/AAC.00005-08
Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65:27–37.
pubmed: 18333863
pmcid: 2311406
doi: 10.1111/j.1365-2125.2008.03133.x
Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57:3536–46.
pubmed: 23669385
pmcid: 3719771
doi: 10.1128/AAC.00292-13
Merli M, Galli L, Marinaro L, Ariaudo A, Messina E, Uberti-Foppa C, et al. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. J Antimicrob Chemother. 2017;72:812–5.
pubmed: 27999010
Greener BN, Patterson KB, Prince HMA, Sykes CS, Adams JL, Dumond JB, et al. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J Acquir Immune Defic Syndr. 2013;64:39–44.
pubmed: 23945251
pmcid: 3804901
doi: 10.1097/QAI.0b013e31829ed7a4
Singh RP, Adkison K, Wolstenholme A, Hopking J, Wynne B. Pharmacokinetics, safety, and tolerability of a single oral dose of abacavir/dolutegravir/lamivudine combination tablets in healthy Japanese study participants. Clin Pharmacol Drug Dev. 2021;10:985–93.
pubmed: 34265164
pmcid: 8456852
doi: 10.1002/cpdd.996
Courlet P, Stader F, Guidi M, Alves Saldanha S, Stoeckle M, Cavassini M, et al. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. AIDS. 2019;34:103–8.
doi: 10.1097/QAD.0000000000002372
Blackman AL, Heil EL, Devanathan AS, Pandit NS. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report. Antivir Ther. 2020;25:115–9.
pubmed: 32341207
pmcid: 8351529
doi: 10.3851/IMP3355
Brooks KM, Garrett KL, Kuriakose SS, George JM, Balba G, Bailey B, et al. Decreased absorption of dolutegravir and tenofovir disoproxil fumarate, but not emtricitabine, in an HIV-infected patient following oral and jejunostomy-tube administration. Pharmacotherapy. 2017;37:e82–9.
pubmed: 28556353
pmcid: 5559318
doi: 10.1002/phar.1960
Gallant JE, Thompson M, DeJesus E, Voskuhl GW, Wei X, Zhang H, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquired Immune Defic Syndr. 2017;75:61–6.
doi: 10.1097/QAI.0000000000001306
Stader F, Courlet P, Decosterd LA, Battegay M, Marzolini C. Physiologically based pharmacokinetic modelling combined with Swiss HIV Cohort Study data supports no dose adjustment of bictegravir in elderly individuals living with HIV. Clin Pharmacol Ther. 2021;109(4):1025–9.
pubmed: 33521960
pmcid: 8048864
doi: 10.1002/cpt.2178
Tempestilli M, D’Avolio A, De Nicolò A, Agrati C, Antinori A, Cicalini S. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. J Antimicrob Chemother. 2021;76(12):3320–2.
pubmed: 34450632
doi: 10.1093/jac/dkab319
Salama E, Hill L, Patel N, Best BM, Momper JD. Brief report: pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV. J Acquir Immune Defic Syndr. 2021;88:389–92.
pubmed: 34285156
doi: 10.1097/QAI.0000000000002765
Hocqueloux L, Lefeuvre S, Bois J, Valentin C, Brucato S, Alix A, et al. Bioavailability of solid vs. dissolved vs. crushed single-tablet of bictegravir/emtricitabine/tenofovir alafenamide in HIV negative volunteers: the SOLUBIC study. HIV Med. 2021;22:132–3.
Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62:533–40.
pubmed: 25450717
doi: 10.1016/j.jhep.2014.10.035
Custodio JM, Fordyce M, Garner W, Vimal M, Ling KHJ, Kearney BP, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother. 2016;60:5135–40.
pubmed: 27216057
pmcid: 4997827
doi: 10.1128/AAC.00005-16
Begley R, Das M, Zhong L, Ling J, Kearney BP, Custodio JM. Pharmacokinetics of tenofovir alafenamide when coadministered with other hiv antiretrovirals. J Acquired Immune Defic Syndr. 2018;78:465–72.
doi: 10.1097/QAI.0000000000001699
Di Perri G, Green B, Morrish G, Hill A, Faetkenheuer G, Bickel M, et al. Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients. HIV Clin Trials. 2013;14:92–8.
pubmed: 23835511
doi: 10.1310/hct1403-92
Kakuda T, Sekar V, Vis P, Coate B, Ryan R, Anderson D, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the gender, race, and clinical experience (GRACE) trial. AIDS Res Treat. 2012;2012: 186987.
pubmed: 22536495
pmcid: 3318205
Calcagno A, Trentalange A, Simiele M, Marinaro L, Patti F, Tettoni MC, et al. Rilpivirine pharmacokinetics in 3 HIV-positive patients with liver cirrhosis concomitantly receiving pantoprazole. Ther Drug Monit. 2015;37:695–6.
pubmed: 26378373
doi: 10.1097/FTD.0000000000000200
Lamorde M, Walimbwa S, Byakika-Kibwika P, Katwere M, Mukisa L, Sempa JB, et al. Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother. 2014;70:1482–6.
doi: 10.1093/jac/dku575
Custodio JM, Chuck SK, Chu H, Cao H, Ma G, Flaherty J, et al. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide. Pharmacol Res Perspect. 2017;5(5): e00353.
pubmed: 28971607
pmcid: 5625157
doi: 10.1002/prp2.353
Dickinson L, Yapa HM, Jackson A, Moyle G, Else L, Amara A, et al. Plasma tenofovir, emtricitabine, and rilpivirine and intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetics following drug intake cessation. Antimicrob Agents Chemother. 2015;59:6080–6.
pubmed: 26195515
pmcid: 4576083
doi: 10.1128/AAC.01441-15
Mathias A, Menning M, Wiser L, Wei X, Dave A, Chuck S, et al. Bioequivalence of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate single tablet regimen. J Bioequivalence Bioavailab. 2012;4:100–5.
Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, et al. Severe renal impairment has minimal impact on doravirine pharmacokinetics. Antimicrob Agents Chemother. 2018;62(8):e00326-e418.
pubmed: 29891610
pmcid: 6105803
doi: 10.1128/AAC.00326-18
Behm MO, Yee KL, Fan L, Fackler P. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects. Antiviral Ther. 2017;22:337–44.
doi: 10.3851/IMP3142
Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, Van Bortel L, Dockendorf MF, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antiviral Ther. 2015;20:397–405.
doi: 10.3851/IMP2920
Calza L, Colangeli V, Magistrelli E, Bussini L, Conti M, Ramazzotti E, et al. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. HIV Med. 2017;18:474–81.
pubmed: 28116848
doi: 10.1111/hiv.12478
Kakuda TN, Leopold L, Timmers M, Van De Casteele T, Hillewaert V, Tomaka FL, et al. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. Int J Clin Pharmacol Ther. 2014;52:805–16.
pubmed: 25109510
doi: 10.5414/CP202066
Cojutti PG, Londero A, Della Siega P, Givone F, Fabris M, Biasizzo J, et al. Comparative population pharmacokinetics of darunavir in SARS-CoV-2 patients vs. HIV patients: the role of interleukin-6. Clin Pharmacokinet. 2020;59:1251–60.
Dufty NE, Gilleran G, Hawkins D, Else LJ, Taylor S. Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. J Antimicrob Chemother. 2013;68:972–4.
pubmed: 23249840
doi: 10.1093/jac/dks486
Vourvahis M, Fang J, Checchio T, Milton A, Weatherley B, McFadyen L, et al. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. HIV Clin Trials. 2013;14:99–109.
pubmed: 23835512
doi: 10.1310/hct1403-99
World Health Organization (WHO). WHO recommends dolutegravir as preferred HIV treatment option in all populations. 2019. https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations#:~:text=Based%20on%20new%20evidence%20assessing,and%20those%20of%20childbearing%20potential . Accessed 4 Nov 2022.
Elliot ER, Wang X, Singh S, Simmons B, Vera JH, Miller RF, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019;68:87–95.
pubmed: 29771285
doi: 10.1093/cid/ciy426
Zhang J, Hayes S, Sadler BM, Minto I, Brandt J, Piscitelli S, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80:502–14.
pubmed: 25819132
pmcid: 4574835
doi: 10.1111/bcp.12639
Calcagno A, Trunfio M, D’Avolio A, Di Perri G, Bonora S. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. Expert Opin Drug Metab Toxicol. 2021;17:665–76.
pubmed: 33913394
doi: 10.1080/17425255.2021.1915285
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/what-start-initial-combination-regimens?view=full .
Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses. 2010;26:635–43.
pubmed: 20560793
pmcid: 2932550
doi: 10.1089/aid.2009.0154
Stader F, Courlet P, Kinvig H, Battegay M, Decosterd LA, Penny MA, et al. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. Br J Clin Pharmacol. 2020;87(2):458–70.
pubmed: 32470203
doi: 10.1111/bcp.14402
Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52:4228–32.
pubmed: 18838586
pmcid: 2592888
doi: 10.1128/AAC.00487-08
Moltó J, Valle M, Back D, Cedeño S, Watson V, Liptrott N, et al. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. Antimicrob Agents Chemother. 2011;55:72–5.
pubmed: 20937791
doi: 10.1128/AAC.00789-10
Yu CY, Campbell SE, Sponseller CA, Small DS, Medlock MM, Morgan RE. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Invest. 2014;34:475–82.
doi: 10.1007/s40261-014-0198-x
Wassner C, Bradley N, Lee Y. A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231.
pubmed: 32295453
pmcid: 7163232
doi: 10.1177/2325958220919231
Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an UNGAP review. Eur J Pharm Sci. 2021;162: 105812.
pubmed: 33753215
doi: 10.1016/j.ejps.2021.105812
Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, et al. Impact of gastrointestinal physiology on drug absorption in special populations––an UNGAP review. Eur J Pharm Sci. 2020;147: 105280.
pubmed: 32109493
doi: 10.1016/j.ejps.2020.105280
US FDA. BIKTARVY: Highlights of prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf . Accessed 26 Jan 2021.
Cimino C, Binkley A, Swisher R, Short WR. Antiretroviral considerations in HIV-infected patients undergoing bariatric surgery. J Clin Pharm Ther. 2018;43:757–67.
pubmed: 30110123
doi: 10.1111/jcpt.12755
Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78:1817–28.
pubmed: 30460547
pmcid: 6424950
doi: 10.1007/s40265-018-1010-7
Kanmogne G, Woollard S. Maraviroc: a review of its use in HIV infection and beyond. Drug Des Dev Ther. 2015;2:5447.
doi: 10.2147/DDDT.S90580